What’s new in atrial fibrillation?

1. Dabigatran therapy with a 150mg dose bid in AF patients was shown to be safe and effective with a hazard ratio of:

2. In the RE-LY study, what percentage of patients was given a standard dose (150mg bid) as compared to a reduced dose (110mg bid)?

3. In real-world patients, a dabigatran standard dose as compared to a low dose closely reflects what was seen in the RE-LY cohort:

4. In real-world patients, use of FXa inhibitors such as rivaroxaban closely reflects what was seen in the relevant phase III trial:

5. Real-world registries such as GLORIA-AF closely mimic actual phase III trials except that:

6. In the real world internationally, what percentage of AF patients are still taking their medication after two years?

7. When performing ablation in dabigatran-treated AF patients, anticoagulant therapy should be:

8. The incidence of major bleeding events on dabigatran versus warfarin treatment during and up to eight weeks post-ablation was:

9. In the RE-DUAL PCI trial, dual antithrombotic therapy with dabigatran plus a P2Y₁₂ inhibitor reduced the risk of bleeding compared to triple therapy with warfarin, AP2Y₁₂ inhibitor and aspirin:

10. In the RE-DUAL PCI trial intracranial haemorrhage occurred in what percentage of patients treated with dual therapy (dabigatran 150mg plus P2Y₁₂ inhibitor)?

11. The incidence of major bleeding on DOAC therapy that requires a reversal agent in the view of attending clinician is on average:

12. Idarucizumab was registered in South Africa as the reversal agent for dabigatran in:

13. Which of the following statements is false?

14. Andexenet alfa, as a decoy factor X, has been approved in the USA and Europe as a reversal agent in patients treated with:

15. Which statement is false?